ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / GMED
PODD (72) BAX (50) PEN (57) SOLV (44) ⌘ Pro Terminal →

Globus Medical Inc. (GMED) — RQD Stock Rating Cockpit

$79.46 +1.81% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $79.57

Globus Medical Inc. (GMED) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $10.48B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GMED Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GMED stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Globus Medical Inc. (NYSE: GMED) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $79.46 (+1.81% 1D, market cap $10.48B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, GMED ranks #82 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GMED compare to PODD and BAX in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), GMED carries a Roarable C+ (69/100 RQD), trailing P/E of 20.7x, gross margin of 67.4%, and ROIC of 8.7%. By comparison, PODD (Insulet Corporation) holds a B grade (72/100 RQD, P/E 42.8x, ROIC 20.4%, cap $10.38B) and BAX (Baxter International Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -2.4%, cap $11.90B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while PODD leads on capital efficiency (20.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GMED?
▼

Per GMED's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001237831), Globus Medical Inc. generated $2.94B in revenue (+16.7% YoY), $537.9M in net income, and $588.8M in free cash flow against $5.30B in total assets and $328.3M in total debt. Key quantitative strengths: Strong cash generator (67.4% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $79.57 (+0.14%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 20% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 69/100 (C+) historically posted market-perform odds over rolling 90-day windows (+2.0% avg 90D alpha vs SPY • 57.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C+
025507510069
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk B
Cash (16)Whales (9)SEC (18)Macro (11)CEO (15)
Each axis scored 0–20
12M PRICE TARGET CONE+4.9% Base Target
$106 Bull$83 Base$65 Bear
📬 FREE GMED RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GMED)Realized 20D OHLCV Swing Band: ±6%
Deterministic 5-Pillar Attribution (69/100 Composite)
🔍 WHY GMED SCORES 69/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (26% of score)

Altman Z-Score 10.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▲ #2 Bullish Driver: Cash Engine Quality+16/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 20% FCF Margin ($588.8M FCF) & 67.4% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning9/20 pts (-11 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
61
Grade C$76.31+3.1% Next Q
Q2 (-2Q)
64
Grade C+$78.68+3.3% Next Q
Q3 (-1Q)
66
Grade B-$81.26-2.2% Next Q
Current
69
Grade C+$79.46+2% Hist 90D α
Trajectory: C (61) → C+ (69)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the GMED Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 69/100 (C+) score, GMED faces multiple-compression risk if 20.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 64.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($77.41) or 200D SMA ($83.31) invalidates the momentum regime and cuts Target Base ($83.39) toward Bear Floor ($65.04).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GMED• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GMED Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 69%NO 31%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
4830 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
10.74>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
9 / 99-Pt Accounting
52-WEEK LASER RANGE48% OF RANGE
L: $60$79.46H: $101
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (67.4% gross margin and healthy balance-sheet cushion).

Factor Grade: B+RQD 16 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: C-RQD 24 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: BRQD 29 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on GMED

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (80)

8.7% ROIC with 67.4% gross margin and 5.29% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (90)

Altman-Z 10.74 and Piotroski 9/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
NEUTRAL (58)

24/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like GMED
  • ✓Strong cash generator (67.4% gross margin)—profits are backed by real money, not accounting tricks.
  • ✓Company leadership has skin in the game with net positive insider conviction.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Broader market pullbacks can still drag down strong stocks in the short run.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (GMED Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
GMED // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -12.30%📐 HORIZONTAL RANGE
2026-11-03O $82.91H $82.91L $78.05C $79.46VOL 1.68M
RES: $82.99SUP: $72.17SMA50: $77.41SMA200: $83.31
$93.38$87.73$82.09$76.44$70.79RES $82.99SUP $72.17$79.462026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GMED Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GMED Butterfly Map → + Track GMED →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
14.3%/yr Implied 5Y Growth

vs. +16.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on GMED today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GMED. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GMED today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GMED)

Health Care Rank #82 of 1015 ⚔️ PODD vs GMED Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GMED vs. PODD, BAX, PEN, SOLV)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Globus Medical Inc. (GMED) ranks #82 by composite RQD confidence (69/100, grade C+) and #103 by equity capitalization ($10.48B). Within this direct 5-issuer industry benchmark cohort, SOLV leads on earnings valuation at 9.1x trailing P/E, while PODD leads on capital efficiency and profitability with 20.4% ROIC and 71.6% gross margin. PODD currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with GMED at 69/100 (C+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
GMED ACTIVE
Globus Medical Inc.
C+ 69/100 20.7x 67.4% 8.7% +1.81% $10.48B Benchmark Subject
PODD
Insulet Corporation
B 72/100 42.8x 71.6% 20.4% +2.63% $10.38B /podd-vs-gmed →
BAX
Baxter International Inc.
D 50/100 — 30.1% -2.4% +5.30% $11.90B /bax-vs-gmed →
PEN
Penumbra Inc.
D+ 57/100 71.4x 67.1% 10.6% +0.75% $12.57B /pen-vs-gmed →
SOLV
Solventum Corporation
D 44/100 9.1x 53.5% 18.7% +4.21% $13.84B /solv-vs-gmed →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001237831 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Globus Medical Inc. (GMED) reported GAAP revenue of $2.94B (+16.7% vs. FY2024 revenue of $2.52B , and +87.4% cumulative change since FY2023) , GAAP net income of $537.9M, operating cash flow of $753.4M, and free cash flow of $588.8M (+45.3% YoY). On the balance sheet, GMED closed FY2025 with $5.30B in total assets against $328.3M in total debt (Altman Z-Score: 10.74, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.94B $537.9M $753.4M $588.8M $5.30B $328.3M
FY2024 (FY) 2024-12-31 $2.52B $103.0M $520.6M $405.2M $5.25B $483.5M
FY2023 (FY) 2023-12-31 $1.57B $122.9M $243.5M $172.9M $6.12B $1.43B

3. GMED Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GMED stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Globus Medical Inc. (NYSE: GMED) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $79.46 (+1.81% 1D, market cap $10.48B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, GMED ranks #82 in composite RQD confidence.

How does GMED compare to PODD and BAX in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), GMED carries a Roarable C+ (69/100 RQD), trailing P/E of 20.7x, gross margin of 67.4%, and ROIC of 8.7%. By comparison, PODD (Insulet Corporation) holds a B grade (72/100 RQD, P/E 42.8x, ROIC 20.4%, cap $10.38B) and BAX (Baxter International Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -2.4%, cap $11.90B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while PODD leads on capital efficiency (20.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GMED?

Per GMED's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001237831), Globus Medical Inc. generated $2.94B in revenue (+16.7% YoY), $537.9M in net income, and $588.8M in free cash flow against $5.30B in total assets and $328.3M in total debt. Key quantitative strengths: Strong cash generator (67.4% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GMED trading relative to its 50-day, 200-day, and 52-week technical levels?

GMED last traded at $79.46 (+1.81% on volume of 1,513,192 shares), positioning the stock +2.65% above its 50-day simple moving average ($77.41) and -4.62% below its 200-day simple moving average ($83.31). Across its 52-week range of $59.51 to $101.40, GMED sits at the 47.6% percentile with a 14-day RSI of 48.0 (NEUTRAL RANGE) and an implied next-earnings move of ±6.0% ($74.69 to $84.23).

Direct Sub-Reports: GMED RQD Cockpit GMED 12M Forecast GMED Earnings & Move GMED Dividends & DRIP GMED Insiders & 13F GMED Whale Options GMED Profit Sankey GMED News & Why
ROARABLE RATING BRIEF • RQD 69/100 (C+) ✓ SEC XBRL & RQD VERIFIED

GMED — Globus Medical Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Globus Medical Inc. (GMED) earns a live Roarable RQD composite score of 69/100, corresponding to a C+ letter grade (Roarable Hold) at a spot price of $79.46 (+1.81% 1D, market capitalization $10.48B).

  • Fundamental Cash Engine (16/20): Anchored by return on invested capital (ROIC) of 8.7%, gross margin of 67.4%, operating margin of 16.3%, and free cash flow yield of 5.29%.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (18/20): Incorporates a 1.07x equity beta, Altman Z-Score of 10.74, Piotroski F-Score of 9/9, and Debt/Equity of 0.07x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Globus Medical Inc. (GMED) is a NYSE-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry. Beyond the sector and industry classification, the product lines, customer base, and revenue model are — The source does record a gross margin of 67.4%, an operating margin of 16.3%, and a net margin of 18.3%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Globus Medical Inc. (GMED) reported $2.94B in annual revenue (up from $2.52B in FY2024, +16.7% YoY) and $537.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.57B revenue, $122.9M net income) through FY2025, GMED scaled operating cash flow to $753.4M and free cash flow to $588.8M, backed by $5.30B in total assets against $328.3M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C+ • RQD 69/100): Strong cash generator (67.4% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 16/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $59.51 – $101.40 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 20.7x trailing P/E and 17.6x EV/EBITDA against 16.3% operating margins and a 1.07x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), GMED carries a macro regime beta of 1.07 and gross margin of 67.4%.

  • Key Question #1: Can GMED sustain or expand its 16.3% operating margin and 8.7% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $2.94B and free cash flow of $588.8M, how will capital allocation balance growth reinvestment against $328.3M in total debt?
  • Key Question #3: How sensitive is GMED's 17.4x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.07x)?

GMED Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Globus Medical Inc. (GMED) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GMED Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GMED Bull vs. Bear Conversation Board — What's Your Call at $79.46?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GMED 🐻 33% BEARISH CONVICTION
1. Pick Your Side on GMED:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $96.78 (+24.0%)
📌 Pinned Debate

Forensic balance sheet scores 18/20 with an Altman Z-Score of 10.74, a Piotroski F-Score of 9/9, and Debt/Equity of 0.07, with debt red

Here is why I am bullish on GMED here at $78.05: Forensic balance sheet scores 18/20 with an Altman Z-Score of 10.74, a Piotroski F-Score of 9/9, and Debt/Equity of 0.07, with debt reduced from $1.43B in FY 2023 to $328.3M in FY 2025.. Compare GMED's 16.3% operating margin and 8.7% ROIC against the rest of Medical/Dental Instruments. As long as cash conversion holds up, dips toward $74.15 are getting bought.

VolSurface_Trader 🐂 BULL

@BearTrap_Alert Shorting a 9/20 institutional whale-flow stock at $78.05 is dangerous when funds are rotating into Health Care.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $61.66 (-21.0%)
Spot @ $78.05

Macro regime fit scores only 11/20 with a beta of 1.07, and analysts are reported as split, with a fair value cut flagged as a RED risk

Sitting on the sidelines or leaning short GMED above $78.05. Macro regime fit scores only 11/20 with a beta of 1.07, and analysts are reported as split, with a fair value cut flagged as a RED risk-watch item.. Until Fundamental Cash Engine (16/20) and FCF yield (5.29%) inflect higher, upside is capped near $101.40.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%